Cited 3 times in
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.